Drug class
Recombinant human interferon gamma (IFN-γ); immunomodulatory cytokine biologic
Mechanism of action
Binds the interferon-gamma receptor and activates JAK1/JAK2-STAT1 signalling, inducing interferon-responsive genes and enhancing macrophage activation and antigen presentation.
General use cases
- Potential use in chronic granulomatous disease or other immune disorders depends on the specific interferon gamma product; binetrakin itself has no independently confirmed current marketing authorisation indication in the reviewed sources
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
